New Formulation of Generic Asthma Drug Launched
Pulmicort Respules had annual sales of $217 million in the United States for 2015.
Teva Pharmaceutical Industries Ltd has launched a new strength, 1 mg/2 mL, of the generic version of budesonide inhalation suspension (Pulmicort Respules).
The product is an inhaled corticosteroid treatment for long-term maintenance to control and prevent asthma symptoms in children aged 1 to 8 years.
Teva now offers the product in all strengths: 0.25 mg/2 mL, 0.5 mg/2 mL, and 1 mg/2 mL.
IMS Health reported that Pulmicort Respules had annual sales of $217 million in the United States for the fiscal year ending in November 2015.
The most common adverse effects associated with the use of Pulmicort Respules are respiratory infection, rhinitis, coughing, and viral infection. Diarrhea, abdominal pain, and vomiting have also occurred.
However, more serious adverse effects have also been observed in some patients. These include anaphylaxis, immunosuppression, hypercorticism, and adrenal suppression.
AstraZeneca is the original manufacturer of Pulmicort Respules.
